The claimed invention is:

1. A compound of formula (Ia):



(Ia)

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate, or solvate thereof, wherein:

R^1 is a saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl or (C_5-C_{10})heteroaryl, (C_5-C_{10})aryloxy or (C_5-C_{10})heteroaryloxy, (C_5-C_{10})ar(C_1-C_6)alkyl or (C_5-C_{10})heteroar(C_1-C_6)alkyl, (C_5-C_{10})ar(C_1-C_6)alkoxy or (C_5-C_{10})heteroar(C_1-C_6)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl, (C_1-C_6)alkyl- and di(C_1-C_6)alkylamino, cyano, nitro, carbamoyl, (C_1-C_6)alkylcarbonyl, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylaminocarbonyl, di(C_1-C_6)alkylaminocarbonyl, (C_5-C_{10})arylcarbonyl, (C_5-C_{10})aryloxycarbonyl, (C_1-C_6)alkylsulfonyl, and (C_5-C_{10})arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy,

(C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkyl HN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, $Ph(CH_2)_{1-6}HN$-, and (C_1-C_6)alkylHN-;

s is an integer from one to five;

R^4 is independently selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-S-(C_1-C_6)alkyl-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, aminoalkyl, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkylHN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-((C_1-C_6)alkyl)-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, ((C_1-C_6)alkyl)$_2$-N-(C=O)-, phenyl-NH-(C=O)-,

phenyl-[(C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-O-, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, and (C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^4 is optionally substituted by at least one substituent independently selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, NC-, HO-, Ph $(CH_2)_{1-6}HN$-, (C_1-C_6)alkylHN-, (C_5-C_{10})heteroaryl and (C_5-C_{10})heterocyclyl;

R^6 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-(SO_2)-, (C_1-C_6)alkyl-(SO_2)-(C_1-C_6)alkyl, phenyl-(SO_2)-, H_2N-(SO_2)-, (C_1-C_6)alkyl-NH-(SO_2)-, (C_1-C_6)alkyl-(SO_2)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(SO_2)-(C_1-C_6)alkyl, ((C_1-C_6)alkyl)$_2$N-(SO_2)-, phenyl-NH-(SO_2)-, (phenyl)$_2$N-(SO_2)-, (C_1-C_6)alkyl-(C=O)-, (C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-(C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-O-(C=O)-, (C_5-C_{10})heterocyclic-O-(C=O)-, (C_3-C_{10})cycloalkyl-O-(C=O)-, H_2N-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, phenyl-NH-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-(C_3-C_{10})cycloalkyl, (C_3-C_{10})cycloalkyl-(C=O)-NH-(C_3-C_{10})cycloalkyl, ((C_1-C_6)alkyl)$_2$N-(C=O)-, (phenyl)$_2$N-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heterocyclic-[((C_1-C_6)alkyl)-N]-(C=O)-, and (C_3-C_{10})cycloalkyl-[((C_1-C_6)alkyl)-N]-(C=O)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^6 is optionally substituted with at least one moiety independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, perhalo$(C_1$-$C_6)$alkyl, $(C_3$-$C_{10})$cycloalkyl, phenyl, benzyl, $(C_5$-$C_{10})$heterocyclic, $(C_5$-$C_{10})$heteroaryl, $(C_1$-$C_6)$alkyl-SO_2-, formyl, NC-, $(C_1$-$C_6)$alkyl-(C=O)-, (C_3C_{10})cycloalkyl-(C=O)-, phenyl-(C=O)-, $(C_5$-$C_{10})$heterocyclic-(C=O)-, $(C_5$-$C_{10})$heteroaryl-(C=O)-, HO-(C=O)-, $(C_1$-$C_6)$alkyl-O-(C=O)-, $(C_3$-$C_{10})$cycloalkyl-O-(C=O)-, $(C_5$-$C_{10})$heterocyclic-O-(C=O)-, $(C_1$-$C_6)$alkyl-NH-(C=O)-, $(C_3$-$C_{10})$cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-, $(C_5$-$C_{10})$heterocyclic-NH-(C=O)-, $(C_5$-$C_{10})$heteroaryl-NH-(C=O)-, $((C_1$-$C_6)$alkyl$)_2$-N-(C=O)-, phenyl-[$((C_1$-$C_6)$alkyl)-N]-(C=O)-, hydroxy, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy, $(C_3$-$C_{10})$cycloalkyl-O-, phenoxy, $(C_5$-$C_{10})$heterocyclic-O-, $(C_5$-$C_{10})$heteroaryl-O-, $(C_1$-$C_6)$alkyl-(C=O)-O-, $(C_3$-$C_{10})$cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, $(C_5$-$C_{10})$heterocyclic-(C=O)-O-, $(C_5$-$C_{10})$heteroaryl-(C=O)-O-, O_2N-, amino, $(C_1$-$C_6)$alkylamino, $((C_1$-$C_6)$alkyl$)_2$-amino, formamidyl, $(C_1$-$C_6)$alkyl-(C=O)-NH-, $(C_3$-$C_{10})$cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-, $(C_5$-$C_{10})$heterocyclic-(C=O)-NH-, $(C_5$-$C_{10})$heteroaryl-(C=O)-NH-, $(C_1$-$C_6)$alkyl-(C=O)-[$(C_1$-$C_6)$alkyl)-N]-, phenyl-(C=O)-[$(C_1$-$C_6)$alkyl-N]-, $(C_1$-$C_6)$alkyl-SO_2NH-, $(C_3$-$C_{10})$cycloalkyl-SO_2NH-, phenyl-SO_2NH-, $(C_5$-$C_{10})$heterocyclic-SO_2NH- and $(C_5$-$C_{10})$heteroaryl-SO_2NH-;

wherein the phenyl or heteroaryl moiety of a R^6 substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, perfluoro$(C_1$-$C_6)$alkyl and perfluoro$(C_1$-$C_6)$alkoxy,

with the proviso that when R^4 is a substituted phenyl group, then (a) R^1 is not a naphthyl, anthracenyl or phenyl and (b) if R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms independently selected from N, O and S, then the fused cyclic ring of said R^1 moiety is substituted; and

with the proviso that when R^4 is hydrogen, then (a) R^1 is not a naphthyl or phenyl and (b) if R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms independently selected from N, O and S, then the fused cyclic ring of said R^1 moiety is substituted; and

with the proviso that when R^4 is not hydrogen or substituted phenyl, then (a) R^1 is not a naphthyl, anthracenyl or phenyl and (b) if R^1 is a phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms independently selected from N, O and S, and is optionally substituted by oxo, then the fused cyclic ring of said R^1 moiety contains at least one substituted heteroatom.

2. A compound of claim 1, wherein R^1 is



, , or .

3. A compound of claim 1, wherein R^1 is





or .

4. A compound of claim 1, wherein R^1 is



or .

5. A compound of claim 1, wherein R^1 is



, , , , , , or ..

6. A compound of claim 1, wherein R^1 is



, , or .

7. A compound of claim 1, wherein R^1 is



, , , , or .

8. A compound of claim 1, wherein R^1 is



or

.

9. A compound of claim 1, wherein s is one to two; R^3 is hydrogen or (C_1-C_6)alkyl; R^4 is hydrogen, (C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_6)alkyl-S-(C_1-C_6)alkyl-, (C_5-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, aminoalkyl, amino(C=O)-, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, or (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl; and R^6 is H, (C_1-C_6)alkyl,
(C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-(SO_2)-(C_1-C_6)alkyl,
(C_1-C_6)alkyl-(SO_2)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(SO_2)-(C_1-C_6)alkyl,
(C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl-(C=O)-(C_3-C_{10})cycloalkyl,
(C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl,
(C_3-C_{10})cycloalkyl-NH-(C=O)-(C_3-C_{10})cycloalkyl, or
(C_3-C_{10})cycloalkyl-(C=O)-NH-(C_3-C_{10})cycloalkyl.

10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. A method of preventing or treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the animal or human suffering from the TGF-related disease state.

12. A method of claim 11, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy,

hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

5